Results 41 to 50 of about 6,421 (186)

A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019 [PDF]

BackgroundTo address the need for treatments for patients with coronavirus disease 2019 (COVID-19), 3 therapies have been given either full approval or Emergency Use Authorization.
Haslam, Alyson, Prasad, Vinay
core   +1 more source

Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study [PDF]

, 2023
Purpose: To investigate the clinical impact of three available antivirals for early COVID-19 treatment in a large real-life cohort. Methods: Between January and October 2022 all outpatients tested positive for SARS-CoV-2 referring to IRCCS S.
Bonazzetti C., Campoli C., Casarini M., Curti S., Gallo M., Giannella M., Malosso M., Marconi L., Marzolla D., Pascale R., Pasquini Z., Riccardi R., Riccucci D., Rinaldi M., Tazza B., Viale P., Zuppiroli A.   +16 more
core   +1 more source

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease [PDF]

Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear.
Antinori, Spinello, Bergna, Annalisa, Bernasconi, Davide, Borghetti, Silvia, Casalini, Giacomo, Colaneri, Marta, Colombo, Valeria, Corbellino, Mario, Cordier, Laura, Dedivitiis, Gianfranco, Fassio, Federico, Gabrieli, Arianna, Galli, Lucia, Gori, Andrea, Lai, Alessia, Riva, Agostino, Rizzardini, Giuliano, Scaglione, Giovanni, Schiavini, Monica, Sollima, Salvatore, Tarkowski, Maciej, Ventura, Carla Della, Visigalli, Debora   +22 more
core   +1 more source

Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands [PDF]

Background: Nirmatrelvir/ritonavir is indicated for the treatment of COVID-19 in symptomatic adults with increased risk for severe illness, not requiring supplemental oxygen yet.
Arteaga Duarte, Carlos H., de Goeij, Michelle H.M., Peters, Michel L., Postma, Maarten J., Spijkerman, Roy   +4 more
core   +1 more source

Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series

Communications Medicine
Background Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection.
Alison K. Cohen, Toni Wall Jaudon, Eric M. Schurman, Lisa Kava, Julia Moore Vogel, Julia Haas-Godsil, Daniel Lewis, Samantha Crausman, Kate Leslie, Siobhan Christine Bligh, Gillian Lizars, JD Davids, Saniya Sran, Michael Peluso, Lisa McCorkell   +14 more
doaj   +1 more source

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial [PDF]

Background: Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that have been proposed as treatments for patients admitted to hospital with COVID-19.
Amuasi, John, Baillie, J Kenneth, Basnyat, Buddha, Buch, Maya H, Campbell, Mark, Chadwick, David, Cooke, Graham, Desai, Purav, Easom, Nicholas, Emberson, Jonathan R, Esmail, Hanif, Faust, Saul N, Ghosh, Dipansu, Hamers, Raph L, Hamilton, Fergus, Haynes, Richard, Hine, Paul, Horby, Peter W, Jaki, Thomas, Jeffery, Katherine, Juszczak, Edmund, Knight, Marian, Landray, Martin J, Lim, Wei Shen, Mafham, Marion, Majumdar, Jaydip, Montgomery, Alan, Mukherjee, Aparna, Mumford, Andrew, Nel, Jeremy, Pessoa-Amorim, Guilherme, Peto, Leon, RECOVERY Collaborative Group, Rowan, Kathryn, Sharp, Sara, Staplin, Natalie, Stewart, Richard, Thwaites, Catherine, Thwaites, Guy, Van Doorn, Hindrik   +39 more
core   +2 more sources

A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.

PLoS ONE, 2023
BackgroundLarge observational studies have demonstrated the real-world effectiveness of nirmatrelvir-ritonavir in preventing severe COVID-19 in higher risk individuals, but have provided limited information on other aspects of nirmatrelvir-ritonavir use.
Valerie Leung, Suzanne Gill, Andrea Llanes, Armughan Khawaja, Amanda Stagg, Janine McCready, Mariana Jacubovich, Grace Ho, Jeff Powis, Christopher Kandel   +9 more
doaj   +1 more source

Pharmacokinetics Profile and Genetics of Double Antiviral Therapy with Remdesivir and Nirmatrelvir/Ritonavir for Prolonged COVID-19 in Patients Treated with Rituximab: A Real-Life Study and Literature Review [PDF]

Introduction: Patients with hematologic malignancies are more likely to develop severe and prolonged SARS-CoV-2 infection, often showing viral persistence despite the use of authorized antivirals. Herein, we report the cases of four patients who received
Alice Palermiti, Antonio D’Avolio, Carlotta Giambra, Cecilia Grosso, Cristina Costa, Elisa Zanotto, Francesca Sidoti, Francesco Giuseppe De Rosa, Ilaria De Benedetto, Jessica Cusato, Luca Scaglione, Martina Billi, Matteo Ferrante, Sara Soloperto, Silvia Corcione, Simone Mornese Pinna, Tommaso Lupia   +16 more
core   +1 more source

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19

SAGE Open Medical Case Reports, 2023
COVID-19 emerged in 2019 and was declared a pandemic by the World Health Organization in March 2020. COVID-19 is highly transmissible and can lead to bilateral pneumonia with severe respiratory failure.
Elizabeth DeMarco, Matthew Turnipseed, Brian Clarke, Farhan Qadeer   +3 more
doaj   +1 more source